WuXi ATU & Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies

WuXi ATU and Wugen announce manufacturing partnership to expedite the delivery of novel cell cancer immunotherapies. WuXi ATU will provide manufacturing and testing services for Wugen’s WU-NK-101, a novel immunotherapy that harnesses the power of memory natural killer (NK) cells to treat cancers.

WuXi ATU’s integrated Contract Testing, Development and Manufacturing Organization (CTDMO) platform will enable Wugen make these life-saving treatments more accessible to patients in need.

Read the full press release: https://bit.ly/3xVumLp